Definitive Contract 75N95025C00010

Award Date 9/30/25
Potential Completion Date 9/29/26
Potential Value $306K
Contracting Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
Set-Aside Type
Total Small Business
Federal Contract Vehicle
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Short Hills, NJ 07078, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for a $299,999 Small Business Innovation Research (SBIR) Phase 1 contract issued by the National Institute of Mental Health (NIMH), which is part of the National Institutes of Health (NIH). The contract was awarded to Vitruvian Bio, LLC, a small, woman-owned, and disadvantaged business, to develop point-of-care assays for measuring HIV viral load and drug adherence. This contract is part of the NIH and Centers for Disease Control and Prevention (CDC) SBIR...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Mental Health (NIMH) to Giner Inc., a small business research and development firm based in Boston. The contract, valued at $306,499.12, is for the development of point-of-care HIV viral load and drug adherence assays. This aligns with NIMH's mission to advance research on mental health and HIV/AIDS. The contract was set aside for small businesses and is part of the broader DHHS SBIR/STTR...
This is a $300,000.00 Firm Fixed Price Definitive Contract awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to Base Pair Biotechnologies Inc., a small business concern, to develop aptasensors for measuring long-term adherence to tenofovir-based and long-acting HIV treatment regimens. The contract was awarded under the Small Business Innovation Research (SBIR) program, which is designed to stimulate technological...
This is a $299,976.31 Firm Fixed Price definitive contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to Guild Associates Inc. (doing business as Guild Biosciences), a small business manufacturer. The contract is for the development of point-of-care HIV viral load and drug adherence assays under the NIH's Small Business Innovation Research (SBIR) program. This work was solicited under SBIR Topic 001 of the anticipated PHS-2024-1...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $430,700.00 firm fixed price contract to High Throughput Biology Inc., a minority-owned, small disadvantaged business, for the development of an array-based multiplex immunoassay for postmortem toxicology screening under the Small Business Innovation Research (SBIR) program. The contract, which is set aside for small businesses, has a completion date of September 24, 2024. High...
This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Definitive Contract to Ai Biosciences, Inc., a minority-owned, self-certified small disadvantaged business, for the development of a low-cost, automated, and rapid home HIV viral load test. The award, which is part of the Small Business Innovation Research (SBIR) Program Phase I, has a potential value of $294,538.00 and a completion date of...
This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Cell Microsystems Inc., a small business manufacturer of tools for cell research. The $283,407.00 contract is for the development of an HIV latent reservoir assay using a microwell array consumable under the Small Business Innovation Research (SBIR) program. This research supports efforts to improve assays for...
<p>This is a $187,493.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Mogene Clinical Diagnostics, LC, a small disadvantaged business. The contract is for the development of a &quot;METHOD FOR THE DETECTION OF MINORITY POPULATIONS OF DRUG RESISTANT HIV&quot;. The award was made on August 11, 2016 with a final completion date of June 14, 2017.</p>
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Program Phase II contract to Aldatu Biosciences, Inc. to develop an assay to detect minor populations of resistant HIV variants in blood specimens from infected individuals with viral loads above 1,000 copies/mL. The firm-fixed-price contract, valued at $2,980,467.00, was awarded on July 30, 2018 with a...

This federal contract award to High Throughput Biology Inc., a minority-owned small disadvantaged business, is for a $306,100 Small Business Innovation Research (SBIR) Phase I contract with the National Institute of Mental Health (NIMH). The contract is for the development of a point-of-care and pharmacy-based antiretroviral drug adherence assay, a quantitative and real-time multiplex immunoassay to monitor antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) medication adherence. This SBIR Phase I award is part of a solicitation issued by the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) that aims to stimulate technological innovation, strengthen the role of small businesses in federal research, and increase commercialization of innovations. The contract has a firm fixed price and is set aside for total small business participation.

Generated 9/27/25, 9:57 AM